Market Research Logo

Duchenne Muscular Dystrophy - Pipeline Review, H2 2015

Duchenne Muscular Dystrophy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Pipeline Review, H2 2015’, provides an overview of the Duchenne Muscular Dystrophy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Duchenne Muscular Dystrophy Overview
Therapeutics Development
Pipeline Products for Duchenne Muscular Dystrophy - Overview
Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis
Duchenne Muscular Dystrophy - Therapeutics under Development by Companies
Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes
Duchenne Muscular Dystrophy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Duchenne Muscular Dystrophy - Products under Development by Companies
Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Asklepios BioPharmaceutical, Inc.
BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company
Capricor Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Dong-A Socio Group
Editas Medicine, Inc.
Eli Lilly and Company
EryDel SPA
FibroGen, Inc.
Galapagos NV
Genethon
GTx, Inc.
Idera Pharmaceuticals, Inc.
Italfarmaco S.p.A.
La Jolla Pharmaceutical Company
Marathon Pharmaceuticals, LLC
Marina Biotech, Inc.
Merck KGaA
MyoTherix Inc.
NicOx S.A.
Nippon Shinyaku Co., Ltd.
nLife Therapeutics, S.L.
Nobelpharma Co., Ltd.
Pfizer Inc.
PhaseBio Pharmaceuticals, Inc.
Prothelia, Inc.
PTC Therapeutics, Inc.
ReveraGen BioPharma, Inc.
Sanofi
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics, Inc.
Shire Plc
Summit Therapeutics Plc
Taiho Pharmaceutical Co., Ltd.
Zambon Company S.p.A.
Duchenne Muscular Dystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AAV1-Foliistatin - Drug Profile
ACE-083 - Drug Profile
alisporivir - Drug Profile
Antisense Oligonucleotide for Duchenne Muscular Dystrophy - Drug Profile
Antisense Oligonucleotide to Activate Dystrophin for Duchene Muscular Dystrophy - Drug Profile
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy - Drug Profile
Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy - Drug Profile
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
arbekacin - Drug Profile
ARM-210 - Drug Profile
AT-300 - Drug Profile
ataluren - Drug Profile
Biostrophin - Drug Profile
BMN-044 - Drug Profile
BMN-045 - Drug Profile
BMN-053 - Drug Profile
BMS-986089 - Drug Profile
CAP-1002 - Drug Profile
CAT-1004 - Drug Profile
CAT-1040 - Drug Profile
CAT-1041 - Drug Profile
DA-4210 - Drug Profile
deflazacort - Drug Profile
dexamethasone sodium phosphate - Drug Profile
domagrozumab - Drug Profile
drisapersen - Drug Profile
Drug for Duchenne Muscular Dystrophy - Drug Profile
Drugs for Duchenne Muscular Dystrophy - Drug Profile
DT-200 - Drug Profile
eteplirsen - Drug Profile
FG-3019 - Drug Profile
Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile
Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
givinostat - Drug Profile
Gtx-027 - Drug Profile
halofuginone hydrobromide - Drug Profile
IB-DMD - Drug Profile
idebenone - Drug Profile
IMO-8400 - Drug Profile
LJPC-30Sa - Drug Profile
LJPC-30Sb - Drug Profile
MG-53 - Drug Profile
MP-101 - Drug Profile
Myomir - Drug Profile
naproxcinod - Drug Profile
NBD Peptide - Drug Profile
NS-065 - Drug Profile
Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile
OSX-200 - Drug Profile
PB-1046 - Drug Profile
poloxamer - Drug Profile
PRO-052 - Drug Profile
PRO-055 - Drug Profile
PRT-01 - Drug Profile
PRT-20 - Drug Profile
Recombinant Protein for Muscular Dystrophy - Drug Profile
Recombinant Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile
Recombinant Proteins for Duchenne Muscular Dystrophy - Drug Profile
rimeporide - Drug Profile
RTC-13 - Drug Profile
SHP-619 - Drug Profile
Small Molecule for Duchenne Muscular Dystrophy - Drug Profile
Small Molecule for Duchenne Muscular Dystrophy - Drug Profile
Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Small Molecules for Duchenne Muscular Dystrophy - Drug Profile
Small Molecules to Target Utrophin for Duchenne Muscular Dystrophy - Drug Profile
SMT-022357 - Drug Profile
SMTC-1100 - Drug Profile
SRP-4008 - Drug Profile
SRP-4044 - Drug Profile
SRP-4045 - Drug Profile
SRP-4050 - Drug Profile
SRP-4052 - Drug Profile
SRP-4053 - Drug Profile
SRP-4055 - Drug Profile
Stem Cell Therapy for Duchenne Muscular Dystrophy - Drug Profile
Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
Stryka-516 - Drug Profile
Stryka-969 - Drug Profile
StrykaPro-1 - Drug Profile
SYN-01 - Drug Profile
tadalafil - Drug Profile
TAS-205 - Drug Profile
TVN-102 - Drug Profile
TXA-127 - Drug Profile
Verolone - Drug Profile
ZP-049 - Drug Profile
Duchenne Muscular Dystrophy - Recent Pipeline Updates
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2015
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by BioMarin Pharmaceutical Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Bristol-Myers Squibb Company, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Debiopharm International S.A., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Dong-A Socio Group, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Editas Medicine, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Eli Lilly and Company, H2 2015
Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H2 2015
Duchenne Muscular Dystrophy - Pipeline by FibroGen, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Genethon, H2 2015
Duchenne Muscular Dystrophy - Pipeline by GTx, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H2 2015
Duchenne Muscular Dystrophy - Pipeline by La Jolla Pharmaceutical Company, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Merck KGaA, H2 2015
Duchenne Muscular Dystrophy - Pipeline by MyoTherix Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Duchenne Muscular Dystrophy - Pipeline by nLife Therapeutics, S.L., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Sanofi, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Shire Plc, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H2 2015
Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015
Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Duchenne Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H2 2015
Duchenne Muscular Dystrophy - Dormant Projects, H2 2015
Duchenne Muscular Dystrophy - Dormant Projects (Contd..1), H2 2015
Duchenne Muscular Dystrophy - Dormant Projects (Contd..2), H2 2015
Duchenne Muscular Dystrophy - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Duchenne Muscular Dystrophy, H2 2015
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report